ASCO QOPI
Quality Oncology Practice Initiative

QOPI® 2022 REPORTING TRACKS

QOPI Certification	IASLC[1]	LMIC[2]	Niarchos Symptom	Niarchos Breast	Niarchos Lung	Niarchos Breast & Lung	Komen Core & Breast	Komen Symptom	Komen Breast	Module	Measure ID	MEASURE	NQF Endorsed Measure (adapted)
X	X	X	X	X	X	X	X	X		Core	1	Pathology report confirming malignancy	
X	X	X	X	X	X	X	X	X		Core	2	Staging documented within one month of first office visit	NQF Endorsed #0386 (adapted)
		X	X	X	X	X	X	X		Core	3	Pain assessed by second office visit	NQF Endorsed #0383/#0384 (adapted)
	X		X	X	X	X	X	X		Core	4a	Pain intensity quantified by second office visit	NQF Endorsed #0384 (adapted)
X			X	X	X	X	X	X		Core	6	Pain addressed appropriately (defect-free measure 3, 4a, 5)	NQF Endorsed #0383 (adapted)
X			X	X	X	X	X	X		Core	6a	Pain assessed on either of the two most recent office visits	NQF Endorsed #0383/#0384 (adapted)
X		X	X	X	X	X	X	X		Core	9	Documented plan for chemotherapy, including doses, route, and time intervals	
X			X	X	X	X	X	X		Core	10	Chemotherapy intent (curative vs. non-curative) documented before	

*QOPI® Certification Measure
1) International Association for the Study of Lung Cancer
2) Low and Middle-Income Countries

QOPI® 2022 REPORTING TRACKS

QOPI Certification	IASLC[1]	LMIC[2]	Niarchos Symptom	Niarchos Breast	Niarchos Lung	Niarchos Breast & Lung	Komen Core & Breast	Komen Symptom	Komen Breast	Module	Measure ID	MEASURE	NQF Endorsed Measure (adapted)
												or within two weeks after administration	
X			X	X	X	X	X	X		Core	11	Chemotherapy intent discussion with patient documented	
		X								Core	12	Number of chemotherapy cycles documented (used in LMIC Track only)	
			X	X	X	X	X	X		Core	13oc4	Documented plan for oral chemotherapy (defect-free Measure, 13oc4a - 13oc4d)	
X			X	X	X	X	X	X		Core	13oc4a	Documented plan for oral chemotherapy: Dose	
X			X	X	X	X	X	X		Core	13oc4b	Documented plan for oral chemotherapy: Administration schedule (start day, days of treatment/rest and planned duration)	
			X	X	X	X	X	X		Core	13oc4c	Documented plan for oral chemotherapy: provided to patient/caregiver prior to start of therapy and practitioner(s) providing continuing	

*QOPI® Certification Measure
1) International Association for the Study of Lung Cancer
2) Low and Middle-Income Countries

ASCO QOPI
Quality Oncology Practice Initiative

QOPI® 2022 REPORTING TRACKS

QOPI Certification	IASLC[1]	LMIC[2]	Niarchos Symptom	Niarchos Breast	Niarchos Lung	Niarchos Breast & Lung	Komen Core & Breast	Komen Symptom	Komen Breast	Module	Measure ID	MEASURE	NQF Endorsed Measure (adapted)
												care (PCP) within 3 months of starting therapy	
			X	X	X	X	X	X		Core	13oc4d	Documented plan for oral chemotherapy: Indications	
			X	X	X	X	X	X		Core	13oc6	Oral chemotherapy monitored on visit/contact following start of therapy (defect-free Measure 13oc6a - 13oc6b)	
			X	X	X	X	X	X		Core	13oc6a	Oral chemotherapy monitored on visit/contact following start of therapy: Medication adherence assessed	
			X	X	X	X	X	X		Core	13oc6b	Oral chemotherapy monitored on visit/contact following start of therapy: Medication adherence addressed	
			X	X	X	X	X	X		Core	14	Signed patient consent for chemotherapy	
X			X	X	X	X	X	X		Core	16	Patient consent for chemotherapy (combined measure, 14, or 15)	

*QOPI® Certification Measure
1) International Association for the Study of Lung Cancer
2) Low and Middle-Income Countries

ASCO QOPI
Quality Oncology Practice Initiative

QOPI® 2022 REPORTING TRACKS

QOPI Certification	IASLC[1]	LMIC[2]	Niarchos Symptom	Niarchos Breast	Niarchos Lung	Niarchos Breast & Lung	Komen Core & Breast	Komen Symptom	Komen Breast	Module	Measure ID	MEASURE	NQF Endorsed Measure (adapted)
X	X		X	X	X	X	X	X		Core	21aa	Smoking status/tobacco use documented in past year	NQF Endorsed #0028 (adapted)
	X		X	X	X	X	X	X		Core	22aa	Smoking/tobacco use cessation counseling recommended to smokers/tobacco users in past year	NQF Endorsed #0028 (adapted)
			X	X	X	X	X	X		Core	22bb	Tobacco cessation counseling administered or patient referred in past year	
X			X	X	X	X	X	X		Core	24	Patient emotional well-being assessed by the second office visit	
X			X	X	X	X	X	X		Core	25	Action taken to address problems with emotional well-being by the second office visit	
X	X		X	X	X	X	X	X		Core	25b	Height, Weight, and BSA documented prior to chemotherapy	
X			X	X	X	X		X		Symptom/ Toxicity	30	Appropriate Antiemetic Therapy for High- and Moderate-Emetic-	

*QOPI® Certification Measure
1) International Association for the Study of Lung Cancer
2) Low and Middle-Income Countries

ASCO QOPI
Quality Oncology Practice Initiative

QOPI® 2022 REPORTING TRACKS

QOPI Certification	IASLC[1]	LMIC[2]	Niarchos Symptom	Niarchos Breast	Niarchos Lung	Niarchos Breast & Lung	Komen Core & Breast	Komen Symptom	Komen Breast	Module	Measure ID	MEASURE	NQF Endorsed Measure (adapted)
												Risk Antineoplastic Agents	
X			X	X	X	X		X		Symptom/ Toxicity	31	Antiemetic Therapy for Low- and Minimal-Emetic-Risk Antineoplastic Agents – Avoidance of Overuse (Lower Score – Better)	
X			X	X	X	X		X		Symptom/ Toxicity	33	Infertility risks discussed prior to chemotherapy with patients of reproductive age	
				X		X	X	X	X	Breast	52	Combination chemotherapy recommended within 4 months of diagnosis for women under 70 with AJCC stage IA (T1c) and IB-III ER/PR negative breast cancer	NQF Endorsed #0559 (adapted)
				X		X	X	X	X	Breast	52a	Complete staging for patients with invasive breast cancer (Cancer stage, HER2, and ER/PR status)	
X				X		X	X	X	X	Breast	53	Combination chemotherapy received within 4	NQF Endorsed #0559 (adapted)

*QOPI® Certification Measure
1) International Association for the Study of Lung Cancer
2) Low and Middle-Income Countries

QOPI® 2022 REPORTING TRACKS

QOPI Certification	IASLC[1]	LMIC[2]	Niarchos Symptom	Niarchos Breast	Niarchos Lung	Niarchos Breast & Lung	Komen Core & Breast	Komen Symptom	Komen Breast	Module	Measure ID	MEASURE	NQF Endorsed Measure (adapted)
												months of diagnosis by women under 70 with AJCC stage IA (T1c) and IB - III ER/PR negative breast cancer	
X				X		X	X	X	X	Breast	54	Test for Her-2/neu overexpression or gene amplification	NQF Endorsed #1878 (adapted)
				X		X	X	X	X	Breast	55	Trastuzumab recommended for patients with AJCC stage I (T1c) to III Her-2/neu positive breast cancer	NQF Endorsed #1858 (adapted)
				X		X	X	X	X	Breast	57a	Appropriate treatment for patients with stage I (T1c) – III HER-2 positive breast cancer	
				X		X	X	X	X	Breast	58	Tamoxifen or AI recommended within 1 year of diagnosis for patients with AJCC stage IA (T1c) and IB - III ER or PR positive breast cancer	NQF Endorsed #0220/#0387 (adapted)
X				X		X	X	X	X	Breast	59	Tamoxifen or AI received within 1 year of diagnosis by	NQF Endorsed #0220/#03

*QOPI® Certification Measure

1) International Association for the Study of Lung Cancer

2) Low and Middle-Income Countries

QOPI® 2022 REPORTING TRACKS

QOPI Certification	IASLC[1]	LMIC[2]	Niarchos Symptom	Niarchos Breast	Niarchos Lung	Niarchos Breast & Lung	Komen Core & Breast	Komen Symptom	Komen Breast	Module	Measure ID	MEASURE	NQF Endorsed Measure (adapted)
												patients with AJCC stage IA(T1c) and IB - III ER or PR positive breast cancer	87 (adapted)
				X		X	X	X	X	Breast	61	Bone modifying agents (IV bisphosphonates or subcutaneous denosumab) administered for breast cancer bone metastases	
				X		X	X	X	X	Breast	62a1	PET, CT, or radionuclide bone scan ordered by practice within 60 days after diagnosis to stage I, IIA, or IIB breast cancer (Lower-Score Better)	
				X		X	X	X	X	Breast	62b1	PET, CT, or radionuclide bone scan ordered by practice between day 61 and day 365 after diagnosis of breast cancer in patients who received treatment with curative intent (Lower-Score Better)	

*QOPI® Certification Measure
1) International Association for the Study of Lung Cancer
2) Low and Middle-Income Countries

ASCO QOPI
Quality Oncology Practice Initiative

QOPI® 2022 REPORTING TRACKS

QOPI Certification	IASLC[1]	LMIC[2]	Niarchos Symptom	Niarchos Breast	Niarchos Lung	Niarchos Breast & Lung	Komen Core & Breast	Komen Symptom	Komen Breast	Module	Measure ID	MEASURE	NQF Endorsed Measure (adapted)
				X		X	X	X	X	Breast	62c1	Serum tumor marker surveillance ordered by practice between 30 days and 365 days after diagnosis of breast cancer in patients who received treatment with curative intent for breast cancer (Lower-Score Better)	
				X		X	X	X	X	Breast	62d	GCSF administered to patients who received chemotherapy for metastatic breast cancer (Lower-Score Better)	
X										Colorectal	68	Adjuvant chemotherapy received within 4 months of diagnosis by patients with AJCC stage III colon cancer	NQF Endorsed #0223/#0385 (adapted)
X										Colorectal	74	RAS (KRAS and NRAS) testing for patients with metastatic colorectal cancer who received anti-EGFR MoAb therapy	NQF Endorsed #1860 (adapted)

*QOPI® Certification Measure
1) International Association for the Study of Lung Cancer
2) Low and Middle-Income Countries

ASCO QOPI
Quality Oncology Practice Initiative

QOPI® 2022 REPORTING TRACKS

QOPI Certification	IASLC[1]	LMIC[2]	Niarchos Symptom	Niarchos Breast	Niarchos Lung	Niarchos Breast & Lung	Komen Core & Breast	Komen Symptom	Komen Breast	Module	Measure ID	MEASURE	NQF Endorsed Measure (adapted)
	X				X	X				NSCLC	81	Adjuvant cisplatin-based chemotherapy received within 60 days after curative resection by patients with AJCC stage II or IIIA NSCLC	
	X				X	X				NSCLC	82	Adjuvant chemotherapy recommended for patients with AJCC stage IA NSCLC (Lower-Score Better)	
	X				X	X				NSCLC	83	Adjuvant radiation therapy recommended for patients with AJCC stage IB or II NSCLC (Lower-Score Better)	
X	X				X	X				NSCLC	84	Performance status documented for patients with initial AJCC stage IV or distant metastatic NSCLC	
X	X				X	X				NSCLC	88	Patients with Stage IV NSCLC with adenocarcinoma histology with an activating EGFR mutation or ALK gene rearrangement who	

*QOPI® Certification Measure
1) International Association for the Study of Lung Cancer
2) Low and Middle-Income Countries

QOPI® 2022 REPORTING TRACKS

QOPI Certification	IASLC[1]	LMIC[2]	Niarchos Symptom	Niarchos Breast	Niarchos Lung	Niarchos Breast & Lung	Komen Core & Breast	Komen Symptom	Komen Breast	Module	Measure ID	MEASURE	NQF Endorsed Measure (adapted)
												received first-line EGFR tyrosine kinase inhibitor or other targeted therapy	
	X				X	X				NSCLC	89	Patients with Stage IV NSCLC with EGFR mutation status unknown or without an activating EGFR mutation or ALK gene rearrangement who received first-line EGFR tyrosine kinase inhibitor or ALK inhibitor (Lower-Score Better)	
X					X	X				NSCLC	89a	GCSF administered to patients who received chemotherapy for metastatic NSCLC cancer (Lower-Score-Better)	
	X				X	X				NSCLC	90	PET or PET-CT ordered by the practice between 0 and 12 months after treatment with curative intent for patients with Stage I or Stage II NSCLC (Lower-Score Better)	

*QOPI® Certification Measure
1) International Association for the Study of Lung Cancer
2) Low and Middle-Income Countries

ASCO QOPI
Quality Oncology Practice Initiative

QOPI® 2022 REPORTING TRACKS

QOPI Certification	IASLC[1]	LMIC[2]	Niarchos Symptom	Niarchos Breast	Niarchos Lung	Niarchos Breast & Lung	Komen Core & Breast	Komen Symptom	Komen Breast	Module	Measure ID	MEASURE	NQF Endorsed Measure (adapted)
	X				X	X				NSCLC	91	Molecular Testing for Patients with Stage IV NSCLC with Adenocarcinoma Histology	
	X				X	X				NSCLC	92	Molecular Testing Turnaround Time for Patients with Stage IV NSCLC with Adenocarcinoma Histology	
	X				X	X				NSCLC	93	Concurrent Chemoradiation for Patients with a Diagnosis of Stage IIIB NSCLC	
	X				X	X				SCLC	118	Prophylactic Cranial Irradiation for Patients with Limited Stage (LS) Small Cell Lung Cancer (SCLC)	
	X				X	X				SCLC	119	Overtreatment of SCLC Patients with Platinum-Based Chemotherapy (Lower-Score Better)	
	X				X	X				SCLC	120	Early Thoracic Radiotherapy (TRT) for Patients with a Diagnosis of Limited Stage SCLC	

*QOPI® Certification Measure
1) International Association for the Study of Lung Cancer
2) Low and Middle-Income Countries